|
|
||||||||
Technical Briefs |
1
Department of Pure and Applied Chemistry, University of Strathclyde, Glasgow G11XR, UK;
2
Department of Pathological Biochemistry, Glasgow Royal Infirmary University NHS Trust, Glasgow G4 OSF, UK;
3
Department of Surgery, Western Glasgow Hospitals University NHS Trust, Glasgow G116NT, UK;
The acute phase plasma protein response is part of the complex series of physiological, hematological, and biochemical events that constitute the inflammatory response after tissue injury or infection. The magnitude and duration of the response are related to the nature and severity of the injury and the presence of sepsis (1). We have previously related alterations in plasma iron, transferrin, zinc, albumin, copper, and ceruloplasmin concentrations after major surgery to a marked rise in plasma C-reactive protein (CRP) concentration (2). In both acute (3)(4) and chronic (5) illnesses, the plasma concentration of selenium also decreases in proportion to the magnitude of the inflammatory response. There is concern about the decline in dietary intake of selenium in some areas of the world (6), because the antioxidant activities of several selenoproteins may be important in preventing free radical damage (7). If plasma selenium concentrations decrease during an inflammatory response, independently of dietary intake, then this would have important implications for the interpretation of the plasma selenium values reported in a wide range of illnesses. In this study, total plasma selenium concentration and changes in plasma selenoproteins after minor elective surgery (inguinal hernia repair) were determined and related to the accompanying alterations in plasma CRP.
Ten male patients (mean age, 51 years; range, 1890 years) requiring
inguinal hernia repair were recruited to the study. All patients were
healthy before surgery, and none were taking any relevant medication.
Samples of head hair and toe nails (80100 mg) were obtained 24 h
before surgery as a measure of long-term selenium nutritional status,
along with venous blood collected into plain (10 mL) and lithium
heparin tubes (20 mL). Blood samples were taken on the mornings of day
1 and day 6 after
Footnotes
References
The following articles in journals at HighWire Press have cited this article:
![]() |
H.-A. Meyer, B. Hollenbach, C. Stephan, T. Endermann, N. G. Morgenthaler, H. Cammann, J. Kohrle, K. Jung, and L. Schomburg Reduced Serum Selenoprotein P Concentrations in German Prostate Cancer Patients Cancer Epidemiol. Biomarkers Prev., September 1, 2009; 18(9): 2386 - 2390. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Renko, P. J. Hofmann, M. Stoedter, B. Hollenbach, T. Behrends, J. Kohrle, U. Schweizer, and L. Schomburg Down-regulation of the hepatic selenoprotein biosynthesis machinery impairs selenium metabolism during the acute phase response in mice FASEB J, June 1, 2009; 23(6): 1758 - 1765. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. G. Boosalis The Role of Selenium in Chronic Disease Nutr Clin Pract, April 1, 2008; 23(2): 152 - 160. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. B Stephensen, G. S Marquis, S. D Douglas, L. A Kruzich, and C. M Wilson Glutathione, glutathione peroxidase, and selenium status in HIV-positive and HIV-negative adolescents and young adults Am. J. Clinical Nutrition, January 1, 2007; 85(1): 173 - 181. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Kohrle, F. Jakob, B. Contempre, and J. E. Dumont Selenium, the Thyroid, and the Endocrine System Endocr. Rev., December 1, 2005; 26(7): 944 - 984. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Kupka, G. I. Msamanga, D. Spiegelman, S. Morris, F. Mugusi, D. J. Hunter, and W. W. Fawzi Selenium Status Is Associated with Accelerated HIV Disease Progression among HIV-1-Infected Pregnant Women in Tanzania J. Nutr., October 1, 2004; 134(10): 2556 - 2560. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. W. Last, V. Cornelius, T. Delves, C. Sieniawska, J. Fitzgibbon, A. Norton, J. Amess, A. Wilson, A. Z.S. Rohatiner, and T. A. Lister Presentation Serum Selenium Predicts for Overall Survival, Dose Delivery, and First Treatment Response in Aggressive Non-Hodgkin's Lymphoma J. Clin. Oncol., June 15, 2003; 21(12): 2335 - 2341. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |